<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350021</url>
  </required_header>
  <id_info>
    <org_study_id>2018-09-20 Version 1.2</org_study_id>
    <nct_id>NCT04350021</nct_id>
  </id_info>
  <brief_title>Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer</brief_title>
  <acronym>METRO</acronym>
  <official_title>Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer - a Two Step Study With a Retrospective Analyses Followed by a Translational Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low dose metronomic chemotherapy (LDMC) in patients with metastatic breast cancer (MBC) is
      used as a palliative regiment with the aim to prolong and improve quality of life. The effect
      of LDMC is not fully elucidated. The aim is to evaluate the effect of LDMC with Capecitabine
      and Cyclophosphamide (CX) and to discover new potential predictive markers and potential
      markers for monitoring treatment effect.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rates</measure>
    <time_frame>From baseline until three months after last dose.</time_frame>
    <description>Radiological and Clinical evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical benefit defined as the proportion of patients with CR(complete respons) or PR(partial respons) and patients with stable disease for 24 weeks or more.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Complete response and Partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From baseline until three months after last dose.</time_frame>
    <description>Radiological and Clinical evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From baseline until death of any course assesed up to one year.</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance and safety assessment</measure>
    <time_frame>From baseline until three months after last dose.</time_frame>
    <description>Clinical evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>From baseline until three months after last dose.</time_frame>
    <description>EORTC-QLQ (Quality of Life Questionnaire)-30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of molecular characteristics in ctDNA (circulating tumor) defined as mutational changes.</measure>
    <time_frame>From baseline until the date of first documented progression or date of death from any cause, whichever came first.</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of CA (cancer associated antigen) 15-3 in relation to treatment effect</measure>
    <time_frame>From baseline until the date of first documented progression or date of death from any cause, whichever came first.</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immune deficiency panel markers defined as changes in immune cell composition</measure>
    <time_frame>From baseline until the date of first documented progression or date of death from any cause, whichever came first.</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <condition>Chemotherapy Effect</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine, Cyclophosphamide</intervention_name>
    <description>Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Metastatic breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written and informed consent

          -  Breast cancer confirmed by histology

          -  Recurrence (local or distant) not possible to cure

          -  Measurable or evaluable disease

          -  Life expectancy of more than tree months

          -  ECOG (Eastern Cooperative Oncology Group) performance 0-2

          -  No or any lines of previous therapies for recurrent disease.

          -  Adequate contraception for patients of Child bearing age.

        Exclusion Criteria:

          -  Clinically significant cardiovascular disease

          -  Non healing wound, Active peptic ulcer or bone fracture

          -  Evidence of any other disease that puts the patient at high risk for treatment-related
             complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Karolina Larsson, Physician</last_name>
    <phone>+4631-3421000</phone>
    <email>karolina.f.larsson@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbro Linderholm, Associate Proffessor</last_name>
    <phone>+4631-3421000</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Goteborg</city>
        <state>Vastra Gotaland</state>
        <zip>405 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nol√® F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002 Jan;13(1):73-80.</citation>
    <PMID>11863115</PMID>
  </reference>
  <reference>
    <citation>Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.</citation>
    <PMID>28564564</PMID>
  </reference>
  <reference>
    <citation>Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4899-905. doi: 10.1200/JCO.2008.17.4789. Epub 2008 Sep 15.</citation>
    <PMID>18794539</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

